Professur für Translationale Frauenheilkunde und Geburtshilfe

Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers (2016) Schmidt MK, Hogervorst F, Van Hien R, Cornelissen S, Broeks A, Adank MA, Meijers H, et al. Journal article Mitomycin C and Capecitabine (MiX Trial) for Therapy of Patients with Metastasized, Breast Cancer Pretreated with Anthracycline (2016) Almstedt K, Fasching P, Scharl A, Rauh C, Rack B, Hein A, Hack C, et al. Journal article rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk (2016) Liu J, Loncar I, Collee JM, Bolla MK, Dennis J, Michailidou K, Wang Q, et al. Journal article Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium (2016) Lei J, Rudolph A, Moysich KB, Behrens S, Goode EL, Bolla MK, Dennis J, et al. Journal article Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients (2016) Wallwiener M, Simoes E, Sokolov AN, Brucker SY, Fasching P, Graf J Journal article An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression (2016) Wyszynski A, Hong CC, Lam K, Michailidou K, Lytle C, Yao S, Zhang Y, et al. Journal article Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, et al. Journal article Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21 (2016) Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, Lemacon A, Droit A, et al. Journal article The PI3K Pathway: Background and Treatment Approaches (2016) Lux MP, Fasching P, Schrauder MG, Hein A, Jud S, Rauh C, Beckmann M Journal article Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29) (2016) Von Minckwitz G, Rezai M, Tesch H, Huober J, Gerber B, Zahm DM, Hilfrich J, et al. Journal article